[HTML] thieme-connect.com

[HTML][HTML] Continuation Rates of the 52-mg Levonorgestrel-releasing Intrauterine System according to the Primary Reason for its Use

L Miranda, MH de Sousa, A Faundes… - Revista Brasileira de …, 2021 - thieme-connect.com
Objective To evaluate whether continuation rates with the 52-mg levonorgestrel-releasing
intrauterine system (LNG-IUS) up to 5 years after placement differed between women using …
被引用次数：3 相关文章

Continuation Rates of the 52-mg Levonorgestrel-releasing Intrauterine System according to the Primary Reason for its Use

L Miranda, MH de Sousa, A Faundes… - Revista Brasileira de …, 2021 - bv.fapesp.br
Objective To evaluate whether continuation rates with the 52-mg levonorgestrel-releasing
intrauterine system (LNG-IUS) up to 5 years after placement differed between women using …

Continuation Rates of the 52-mg Levonorgestrel-releasing Intrauterine System according to the Primary Reason for its Use

L Miranda, MH Sousa, A Faundes, C Juliato - 2021 - lareferencia.info
Objective To evaluate whether continuation rates with the 52-mg levonorgestrelreleasing
intrauterine system (LNG-IUS) up to 5 years after placement differed between women using …

Continuation Rates of the 52-mg Levonorgestrel-releasing Intrauterine System according to the Primary Reason for its Use

L Miranda, MH de Sousa… - Revista brasileira de …, 2021 - pubmed.ncbi.nlm.nih.gov
Objective To evaluate whether continuation rates with the 52-mg levonorgestrel-releasing
intrauterine system (LNG-IUS) up to 5 years after placement differed between women using …
[HTML] nih.gov

[HTML][HTML] Continuation Rates of the 52-mg Levonorgestrel-releasing Intrauterine System according to the Primary Reason for its Use

L Miranda, MH de Sousa, A Faundes… - RBGO Gynecology & …, 2021 - ncbi.nlm.nih.gov
Objective To evaluate whether continuation rates with the 52-mg levonorgestrel-releasing
intrauterine system (LNG-IUS) up to 5 years after placement differed between women using …

Continuation rates of the 52-mg levonorgestrel-releasing intrauterine system according to the primary reason for its use

L Miranda, MH Sousa, A Faundes… - Rev. bras. ginecol …, 2021 - pesquisa.bvsalud.org
Objective To evaluate whether continuation rates with the 52-mg levonorgestrelreleasing
intrauterine system (LNG-IUS) up to 5 years after placement differed between women using …

Continuation Rates of the 52-mg Levonorgestrel-releasing Intrauterine System according to the Primary Reason for its Use.

L Miranda, MH Sousa, A Faundes… - Revista Brasileira de …, 2021 - europepmc.org
Objective To evaluate whether continuation rates with the 52-mg levonorgestrel-releasing
intrauterine system (LNG-IUS) up to 5 years after placement differed between women using …
[HTML] scielo.br

[HTML][HTML] Continuation Rates of the 52-mg Levonorgestrel-releasing Intrauterine System according to the Primary Reason for its Use

L Miranda, MH Sousa, A Faundes… - Revista Brasileira de …, 2021 - SciELO Brasil
Objective To evaluate whether continuation rates with the 52-mg levonorgestrelreleasing
intrauterine system (LNG-IUS) up to 5 years after placement differed between women using …
[PDF] scienceopen.com

[PDF][PDF] Continuation Rates of the 52-mg Levonorgestrel-releasing Intrauterine System according to the Primary Reason for its Use

L Miranda, MH de Sousa, A Faundes… - Rev Bras Ginecol …, 2021 - scienceopen.com
Objective To evaluate whether continuation rates with the 52-mg levonorgestrelreleasing
intrauterine system (LNG-IUS) up to 5 years after placement differed between women using …

Continuation rates of the 52-mg levonorgestrel-releasing intrauterine system according to the primary reason for its use.

L Miranda, MH de Sousa, A Faundes, C Juliato - 2021 - cabidigitallibrary.org
Objective: To evaluate whether continuation rates with the 52-mg levonorgestrel-releasing
intrauterine system (LNG-IUS) up to 5 years after placement differed between women using …